351 results about "Inosine" patented technology

Immunostimulatory compositions described as CpG-like nucleic acids are provided, including nucleic acids having immunostimulatory characteristics of CpG nucleic acid, despite certain substitutions of C, G, or C and G of the CpG dinucleotide. The substitutions can include, among others, exchange of methylated C for C, inosine for G, and ZpY for CpG, where Z is cytosine or dSpacer and Y is inosine, 2-aminopurine, nebularine, or dSpacer. Also provided are methods for inducing an immune response in a subject using the CpG-like nucleic acids. The methods are useful in the treatment of a subject that has or is at risk of developing an infectious disease, allergy, asthma, cancer, anemia, thrombocytopenia, or neutropenia.

The invention provides an oligonucleotide comprising an inosine, and/or a nucleotide containing a base able to form a wobble base pair or a functional equivalent thereof, wherein the oligonucleotide, or a functional equivalent thereof, comprises a sequence which is complementary to at least part of a dystrophin pre-m RNA exon or at least part of a non-exon region of a dystrophin pre-m RNA said part being a contiguous stretch comprising at least 8 nucleotides. The invention further provides the use of said oligonucleotide for preventing or treating DMD or BMD.

Agonists of the adenosine A2 receptor promote the migration of endothelial cells, fibroblasts and epithelial cells. Thus, methods and pharmaceutical compositions useful for treating wounds and promoting wound healing comprise agents which cause stimulation of the adenosine A2 receptor, preferably receptor agonists and adenosine uptake blockers. Preferred agonists include 2-phenylaminoadenosine, 2-para-2-carboxyethylphenyl-amino-5'N-ethylcarboxamidoadenosine, 5'N-ethylcarbox-amidoadenosine, 5'N-cyclo-propyladenosine, 5'N-methylcarboxamidoadenosine and PD-125944. Preferred uptake blockers include dipyridamole, nitrobenzylthio-inosine, dilazep and R75231.

The present invention relates generally to pharmaceutical compositions useful to treat viral diseases. The present invention relates particularly RNA polymerase inhibitors and inosine monophosphate dehydrogenase (IMPDH) inhibitors such as mycophenolate compounds.

The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine.

Methods for producing purine nucleosides, and purine nucleotides, such as inosine and 5′-inosinic acid are provided which include using a bacterium belonging to the genus Bacillus or to the genus Escherichia wherein the purine nucleoside productivity of said bacterium is enhanced by increasing an activity of the YdhL protein. Also disclosed is the amino acid sequence of the YdhL protein from Bacillus amyloliquefaciens and the gene encoding it.

Provided herein are nucleic acid synthesis methods and agents that employ an endonuclease for example, endonuclease V, to introduce a nick into a target DNA including one or more inosine, and uses a DNA polymerase to generate amplicons of the target DNA.

The invention relates to the fields of biological pesticide and microbial fertilizer, and specifically discloses a bacillus subtilis wettable powder containing spore germinator and a preparation method thereof. The wettable powder is composed of the following raw materials in parts by weight: 40 to 70 parts of bacillus subtilis fermentation broth, 20 to 30 parts of filling material (diatomite), 1 to 4 parts of wetting agent (Morwet EFW), 0.2 to 1 part of dispersant (CMC-Na), spore germinator: 0.1 to 0.5 part of L-alanine, 0.1 to 0.5 part of inosine, and 0.5 to 1.5 parts of fructose; UV protector: 0.5 to 2 parts of ascorbic acid, and 0.2 to 1 part of lecithin; dryness protector: 1 to 4 parts of maltose and 0.2 to 1 part of methylcellulose, and 1 to 2 parts of synergist (amino oligosaccharin). After the prepared bacillus subtilis wettable powder is applied to the fields, the spore germination speed is accelerated, the germination rate is high, the fertilizing effect and the plant disease control effect are both prominently improved, the using amount of spores is reduced, and the cost is reduced.

The invention provides an erythrocyte preservative solution. The solution comprises the following components by content: 0.3-0.5g/L of adenine, 25-35g/L of glucose, 6-10g/L of sodium citrate, 0.2-0.4g/L of inosine, 0.2-0.3g/L of chloramphenicol, 0.08-0.12g/L of neomycin sulfate, 2.5-3.5g/L of sodium chloride and 0.04-0.06g/L of sodium dihydrogen phosphate. According to the preservative solution, the preservation period of erythrocytes can be 14 weeks, and the erythrocyte suspension preserved in the solution has a relatively high antigen titer in the preservation period.

The invention discloses a preparation method of ribavirin, comprising the following steps: A, by taking inosine as a raw material, adding acid and a catalyst I for acylation reaction to generate ribofuranose tetraacetate; B, respectively treating the ribofuranose tetraacetate obtained in the step A and 1,2,4-triazole-3-carboxylic acid methyl ester by using active carbon firstly, then uniformly mixing the ribofuranose tetraacetate and the 1,2,4-triazole-3-carboxylic acid methyl ester, and then adding a catalyst II for condensation reaction to obtain a condensation compound; C, subjecting the condensation compound obtained in the step B to ammonolysis in ammonia and methyl alcohol to generate crude ribavirin; and D, carrying out refinement on the crude ribavirin obtained in the step C to obtain pure ribavirin. The method is simple in operation, good in selectivity, clean and environment friendly and high in yield of ribavirin.

The invention relates to a method for separating and purifying four nucleoside chemical ingredients (namely adenine, guanosine, 6-iso inosine and adenosine) from traditional Chinese medicine trichosanthes bark. According to the method, four high-purity monomeric compounds, namely adenine, guanosine, 6-iso inosine and adenosine, are obtained from the trichosanthes bark through the following steps of: (1) preparing a crude trichosanthes bark extract; (2) carrying out crude separation by using a macroporous adsorption resin column; and (3) carrying out separation and purification by using semi-preparative high-performance liquid chromatography: carrying out separation and purification on obtained samples by using the semi-preparative high-performance liquid chromatography, wherein the mobile phase is methanol-water. The method disclosed by the invention has the advantages that the process flow is environment-friendly, the damage to the environment is not serious, and the comprehensive cost is low.

The invention relates to a pharmaceutical composition for treating hepatic fibrosis and a preparation method thereof. The pharmaceutical composition is a formulation prepared from a main ingredient and pharmaceutically acceptable auxiliary materials, wherein the main ingredient comprises 100-300 parts of pirfenidone and 50-150 parts of inosine. The formulation of pirfenidone and inosine is stable in quality, controllable, safe and effective. In clinic, the formulation is mainly used for the treatment of diseases of hepatic fibrosis, cirrhosis, liver cancer, and the like.

Disclosed is an adsorbent including a porous carbon material which is produced from a plant-derived material having a silicon (Si) content of not less than 5 wt. % and which has a value of specific surface area determined by the nitrogen BET method of not less than 10 m²/g, a silicon content of not more than 1 wt. %, and pore volumes determined by the BJH method and the MP method of not less than 0.1 cm³/g. The adsorbent adsorbs indole, uric acid, adenosine, α-amylase, 3-methylindole, tryptophan, indicant, theophylline, inosine 5-monophosphate disodium salt, adenosine 5-triphosphate disodium salt, a fatty acid, a coloring matter, hydrophobic molecules, or an organic matter (for example, organic molecules or a protein) having a number average molecular weight of not less than 1×10² and less than 5×10².

A process for preparing an antiviral medicine "Libaweilin" uses acetyl bacillus brevis ATCC 39311, with starch, peptone, beef paste, sodium chloride, dipotassium hydrogen phosphate, potassium bihydrogen phosphate, defoaming agent and running water as raw materials, and includes fermenting, and synthesis by using the resultant complete bacteria as enzyme source and the inosine as ribosome doner. Its advantages are simple process, low cost and high output rate.

Inosine compounds, compositions comprising an inosine compound and methods for treating or preventing an inflammation disease or a reperfusion disease comprising administering an effective amount of an inosine compound to a patient in need thereof are disclosed.

The present invention relates to a microorganism producing inosine, which is one of purine nucleoside, an important material for 5′-inosinic acid synthesis, and method for producing inosine using the same. More particularly, the present invention relates to a recombinant microorganism of Corynebacterium genus producing inosine at high concentration by inactivating the gene encoding nucleoside hydrolase II and by enhancing the expression of the gene encoding 5′-nucleotidase, which still retains the characteristics of Corynebacterium ammoniagenes CJIP2401 (KCCM-10610).

A process for preparing adenosine from inosine by chemical synthesis method includes such steps as acetylating by excessive acetic anhydride under existence of anhydrous sodium acetate to obtain acetylinosine, chlorinating it by trichloroxyphosphate in pyridine to obtain chloro-acetylinosine, ammonolyzing in ammonia-methanol solution to obtain coarse adenosine, and refining. Its advantage is high output rate.

Provided herein are mutant endonuclease V enzymes that are capable of nicking an inosine-containing DNA sequence. Nucleic acid assays and agents that employ such mutant endonuclease V enzymes to introduce a nick into a target DNA including one or more inosine, and uses a DNA polymerase to generate amplicons of a target DNA are also described.